Brought to you by 
Syros Pharmaceuticals raises $30mm through Series A round
15 Dec 2015
Executive Summary
Syros Pharmaceuticals Inc., a newly established company that aims to develop therapies targeting the switches that control genes, has launched and raised $30mm through its Series A round. Company co-founders Arch Venture Partners and Flagship Ventures led, and were joined by WuXi PharmaTech Corporate Venture Fund and other private investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com